Listed

PTC Therapeutics, Inc.

PTCTNasdaqCIK 1070081HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$357.8m, Q3 FY2026
Operating income$25.1m, Q3 FY2026
Net income−$51.7m, Q3 FY2026
PTC Therapeutics, Inc., income statement, quarterly
Line itemUnitQ4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Revenue$m307Revenue, Q4 FY2023, three months to 2023-12-31$307.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure210Revenue, Q1 FY2024, three months to 2024-03-31$210.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure187Revenue, Q2 FY2024, three months to 2024-06-30$186.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure197Revenue, Q3 FY2024, three months to 2024-09-30$196.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure213Revenue, Q4 FY2024, three months to 2024-12-31$213.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure1,176Revenue, Q1 FY2025, three months to 2025-03-31$1.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure179Revenue, Q2 FY2025, three months to 2025-06-30$178.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure211Revenue, Q3 FY2025, three months to 2025-09-30$211.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure165Revenue, Q4 FY2025, three months to 2025-12-31$164.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure273Revenue, Q1 FY2026, three months to 2026-03-31$272.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure361Revenue, Q2 FY2026, three months to 2026-06-30$360.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure358Revenue, Q3 FY2026, three months to 2026-09-30$357.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m121Research and development, Q4 FY2023, three months to 2023-12-31$121.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure116Research and development, Q1 FY2024, three months to 2024-03-31$116.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure132Research and development, Q2 FY2024, three months to 2024-06-30$132.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure161Research and development, Q3 FY2024, three months to 2024-09-30$161.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure125Research and development, Q4 FY2024, three months to 2024-12-31$124.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure109Research and development, Q1 FY2025, three months to 2025-03-31$109.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure113Research and development, Q2 FY2025, three months to 2025-06-30$113.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure100Research and development, Q3 FY2025, three months to 2025-09-30$100.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure133Research and development, Q4 FY2025, three months to 2025-12-31$133.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure101Research and development, Q1 FY2026, three months to 2026-03-31$100.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure99.2Research and development, Q2 FY2026, three months to 2026-06-30$99.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure105Research and development, Q3 FY2026, three months to 2026-09-30$105.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Selling, general and administrative$m76.3Selling, general and administrative, Q4 FY2023, three months to 2023-12-31$76.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure73.3Selling, general and administrative, Q1 FY2024, three months to 2024-03-31$73.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure69.5Selling, general and administrative, Q2 FY2024, three months to 2024-06-30$69.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure73.5Selling, general and administrative, Q3 FY2024, three months to 2024-09-30$73.5m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure84.7Selling, general and administrative, Q4 FY2024, three months to 2024-12-31$84.7m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure81.0Selling, general and administrative, Q1 FY2025, three months to 2025-03-31$81.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure85.3Selling, general and administrative, Q2 FY2025, three months to 2025-06-30$85.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure84.0Selling, general and administrative, Q3 FY2025, three months to 2025-09-30$84.0m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure96.9Selling, general and administrative, Q4 FY2025, three months to 2025-12-31$96.9m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure86.2Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$86.2m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure80.6Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$80.6m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure80.1Selling, general and administrative, Q3 FY2026, three months to 2026-09-30$80.1m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Operating income$m5.8Operating income, Q4 FY2023, three months to 2023-12-31$5.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure(45.5)Operating income, Q1 FY2024, three months to 2024-03-31−$45.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure(40.2)Operating income, Q2 FY2024, three months to 2024-06-30−$40.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure(54.5)Operating income, Q3 FY2024, three months to 2024-09-30−$54.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure(162)Operating income, Q4 FY2024, three months to 2024-12-31−$162.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure970Operating income, Q1 FY2025, three months to 2025-03-31$970.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure(35.0)Operating income, Q2 FY2025, three months to 2025-06-30−$35.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure3.0Operating income, Q3 FY2025, three months to 2025-09-30$3.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure(71.3)Operating income, Q4 FY2025, three months to 2025-12-31−$71.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure45.0Operating income, Q1 FY2026, three months to 2026-03-31$45.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure149Operating income, Q2 FY2026, three months to 2026-06-30$149.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure25.1Operating income, Q3 FY2026, three months to 2026-09-30$25.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Income tax$m(1.3)Income tax, Q4 FY2023, three months to 2023-12-31−$1.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure6.9Income tax, Q1 FY2024, three months to 2024-03-31$6.9m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure13.4Income tax, Q2 FY2024, three months to 2024-06-30$13.4m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure8.7Income tax, Q3 FY2024, three months to 2024-09-30$8.7m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure(28.8)Income tax, Q4 FY2024, three months to 2024-12-31−$28.8m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure63.3Income tax, Q1 FY2025, three months to 2025-03-31$63.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure(6.2)Income tax, Q2 FY2025, three months to 2025-06-30−$6.2m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure(39.0)Income tax, Q3 FY2025, three months to 2025-09-30−$39.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure(4.1)Income tax, Q4 FY2025, three months to 2025-12-31−$4.1m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure0.3Income tax, Q1 FY2026, three months to 2026-03-31$347.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure14.0Income tax, Q2 FY2026, three months to 2026-06-30$14.0m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure10.6Income tax, Q3 FY2026, three months to 2026-09-30$10.6m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Net income$m(156)Net income, Q4 FY2023, three months to 2023-12-31−$155.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure(91.6)Net income, Q1 FY2024, three months to 2024-03-31−$91.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure(99.2)Net income, Q2 FY2024, three months to 2024-06-30−$99.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure(107)Net income, Q3 FY2024, three months to 2024-09-30−$106.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure(65.9)Net income, Q4 FY2024, three months to 2024-12-31−$65.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure867Net income, Q1 FY2025, three months to 2025-03-31$866.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure(64.8)Net income, Q2 FY2025, three months to 2025-06-30−$64.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure15.9Net income, Q3 FY2025, three months to 2025-09-30$15.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure(135)Net income, Q4 FY2025, three months to 2025-12-31−$135.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure(2.8)Net income, Q1 FY2026, three months to 2026-03-31−$2.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure83.5Net income, Q2 FY2026, three months to 2026-06-30$83.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure(51.7)Net income, Q3 FY2026, three months to 2026-09-30−$51.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Diluted EPS$ per sharenot reported(1.20)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure(1.29)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure(1.39)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.39 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figurenot reported10.04Diluted EPS, Q1 FY2025, three months to 2025-03-31$10.04 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure(0.83)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.83 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure0.20Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figurenot reported(0.03)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure0.92Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure(0.62)Diluted EPS, Q3 FY2026, three months to 2026-09-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Basic EPS$ per sharenot reported(1.20)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure(1.29)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure(1.39)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.39 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figurenot reported11.09Basic EPS, Q1 FY2025, three months to 2025-03-31$11.09 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure(0.83)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.83 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure0.20Basic EPS, Q3 FY2025, three months to 2025-09-30$0.20 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figurenot reported(0.03)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure1.01Basic EPS, Q2 FY2026, three months to 2026-06-30$1.01 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure(0.62)Basic EPS, Q3 FY2026, three months to 2026-09-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure

Balance sheet

Cash and equivalents$508.9m, Q3 FY2026
Long-term debt$536.3m, Q3 FY2026
Shareholders' equity−$191.2m, Q3 FY2026
PTC Therapeutics, Inc., balance sheet, quarterly
Line itemUnitFY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Cash and equivalents$m594Cash and equivalents, FY2023, at 2023-12-31$594.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0001070081-25-000012.Report this figure548Cash and equivalents, Q1 FY2024, at 2024-03-31$548.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-04-25, accession 0001558370-24-005782.Report this figure655Cash and equivalents, Q2 FY2024, at 2024-06-30$654.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-08-08, accession 0001070081-24-000017.Report this figure526Cash and equivalents, Q3 FY2024, at 2024-09-30$526.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0001070081-24-000023.Report this figure780Cash and equivalents, FY2024, at 2024-12-31$779.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-19, accession 0001104659-26-017575.Report this figure1,480Cash and equivalents, Q1 FY2025, at 2025-03-31$1.48bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure1,017Cash and equivalents, Q2 FY2025, at 2025-06-30$1.02bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure673Cash and equivalents, Q3 FY2025, at 2025-09-30$672.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure985Cash and equivalents, FY2025, at 2025-12-31$984.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure834Cash and equivalents, Q1 FY2026, at 2026-03-31$834.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure1,050Cash and equivalents, Q2 FY2026, at 2026-06-30$1.05bn. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure509Cash and equivalents, Q3 FY2026, at 2026-09-30$508.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Current assets$m1,219Current assets, FY2023, at 2023-12-31$1.22bn. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0001070081-25-000012.Report this figure1,169Current assets, Q1 FY2024, at 2024-03-31$1.17bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-04-25, accession 0001558370-24-005782.Report this figure1,358Current assets, Q2 FY2024, at 2024-06-30$1.36bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0001070081-24-000017.Report this figure1,282Current assets, Q3 FY2024, at 2024-09-30$1.28bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0001070081-24-000023.Report this figure1,366Current assets, FY2024, at 2024-12-31$1.37bn. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-19, accession 0001104659-26-017575.Report this figure2,316Current assets, Q1 FY2025, at 2025-03-31$2.32bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure2,273Current assets, Q2 FY2025, at 2025-06-30$2.27bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure2,008Current assets, Q3 FY2025, at 2025-09-30$2.01bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure2,274Current assets, FY2025, at 2025-12-31$2.27bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure2,254Current assets, Q1 FY2026, at 2026-03-31$2.25bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure2,617Current assets, Q2 FY2026, at 2026-06-30$2.62bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure2,538Current assets, Q3 FY2026, at 2026-09-30$2.54bn. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Total assets$m1,896Total assets, FY2023, at 2023-12-31$1.90bn. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0001070081-25-000012.Report this figure1,790Total assets, Q1 FY2024, at 2024-03-31$1.79bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-04-25, accession 0001558370-24-005782.Report this figure1,916Total assets, Q2 FY2024, at 2024-06-30$1.92bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0001070081-24-000017.Report this figure1,842Total assets, Q3 FY2024, at 2024-09-30$1.84bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0001070081-24-000023.Report this figure1,705Total assets, FY2024, at 2024-12-31$1.71bn. XBRL concept us-gaap:Assets. 10-K filed 2026-02-19, accession 0001104659-26-017575.Report this figure2,655Total assets, Q1 FY2025, at 2025-03-31$2.66bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure2,634Total assets, Q2 FY2025, at 2025-06-30$2.63bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure2,644Total assets, Q3 FY2025, at 2025-09-30$2.64bn. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure2,899Total assets, FY2025, at 2025-12-31$2.90bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure2,869Total assets, Q1 FY2026, at 2026-03-31$2.87bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure3,250Total assets, Q2 FY2026, at 2026-06-30$3.25bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure3,208Total assets, Q3 FY2026, at 2026-09-30$3.21bn. XBRL concept us-gaap:Assets. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Current liabilities$m603Current liabilities, FY2023, at 2023-12-31$603.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0001070081-25-000012.Report this figure575Current liabilities, Q1 FY2024, at 2024-03-31$574.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-04-25, accession 0001558370-24-005782.Report this figure610Current liabilities, Q2 FY2024, at 2024-06-30$609.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0001070081-24-000017.Report this figure611Current liabilities, Q3 FY2024, at 2024-09-30$610.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0001070081-24-000023.Report this figure581Current liabilities, FY2024, at 2024-12-31$581.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-19, accession 0001104659-26-017575.Report this figure595Current liabilities, Q1 FY2025, at 2025-03-31$595.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure628Current liabilities, Q2 FY2025, at 2025-06-30$627.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure866Current liabilities, Q3 FY2025, at 2025-09-30$866.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure968Current liabilities, FY2025, at 2025-12-31$968.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure924Current liabilities, Q1 FY2026, at 2026-03-31$923.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure771Current liabilities, Q2 FY2026, at 2026-06-30$771.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure776Current liabilities, Q3 FY2026, at 2026-09-30$776.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Total liabilities$m2,714Total liabilities, FY2023, at 2023-12-31$2.71bn. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0001070081-25-000012.Report this figure2,684Total liabilities, Q1 FY2024, at 2024-03-31$2.68bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-04-25, accession 0001558370-24-005782.Report this figure2,897Total liabilities, Q2 FY2024, at 2024-06-30$2.90bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0001070081-24-000017.Report this figure2,897Total liabilities, Q3 FY2024, at 2024-09-30$2.90bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0001070081-24-000023.Report this figure2,803Total liabilities, FY2024, at 2024-12-31$2.80bn. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-19, accession 0001104659-26-017575.Report this figure2,841Total liabilities, Q1 FY2025, at 2025-03-31$2.84bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure2,841Total liabilities, Q2 FY2025, at 2025-06-30$2.84bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure2,799Total liabilities, Q3 FY2025, at 2025-09-30$2.80bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure3,104Total liabilities, FY2025, at 2025-12-31$3.10bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure3,050Total liabilities, Q1 FY2026, at 2026-03-31$3.05bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure3,416Total liabilities, Q2 FY2026, at 2026-06-30$3.42bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure3,399Total liabilities, Q3 FY2026, at 2026-09-30$3.40bn. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Long-term debt$m284Long-term debt, FY2023, at 2023-12-31$284.2m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2025-02-27, accession 0001070081-25-000012.Report this figure285Long-term debt, Q1 FY2024, at 2024-03-31$284.5m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-04-25, accession 0001558370-24-005782.Report this figure285Long-term debt, Q2 FY2024, at 2024-06-30$284.8m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-08-08, accession 0001070081-24-000017.Report this figure285Long-term debt, Q3 FY2024, at 2024-09-30$285.1m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2024-11-07, accession 0001070081-24-000023.Report this figure285Long-term debt, FY2024, at 2024-12-31$285.4m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-K filed 2026-02-19, accession 0001104659-26-017575.Report this figure286Long-term debt, Q1 FY2025, at 2025-03-31$285.7m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure286Long-term debt, Q2 FY2025, at 2025-06-30$286.0m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figurenot reportednot reportednot reported536Long-term debt, Q2 FY2026, at 2026-06-30$535.5m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure536Long-term debt, Q3 FY2026, at 2026-09-30$536.3m. XBRL concept us-gaap:LongTermDebtNoncurrent. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reported286Current portion of debt, Q3 FY2025, at 2025-09-30$286.3m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure287Current portion of debt, FY2025, at 2025-12-31$286.6m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure287Current portion of debt, Q1 FY2026, at 2026-03-31$286.9m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure55.5Current portion of debt, Q2 FY2026, at 2026-06-30$55.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figurenot reported
Shareholders' equity$m(819)Shareholders' equity, FY2023, at 2023-12-31−$818.6m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-19, accession 0001104659-26-017575.Report this figure(894)Shareholders' equity, Q1 FY2024, at 2024-03-31−$893.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure(980)Shareholders' equity, Q2 FY2024, at 2024-06-30−$980.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure(1,054)Shareholders' equity, Q3 FY2024, at 2024-09-30−$1.05bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure(1,098)Shareholders' equity, FY2024, at 2024-12-31−$1.10bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure(186)Shareholders' equity, Q1 FY2025, at 2025-03-31−$185.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure(207)Shareholders' equity, Q2 FY2025, at 2025-06-30−$206.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure(156)Shareholders' equity, Q3 FY2025, at 2025-09-30−$155.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure(205)Shareholders' equity, FY2025, at 2025-12-31−$205.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure(180)Shareholders' equity, Q1 FY2026, at 2026-03-31−$180.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure(165)Shareholders' equity, Q2 FY2026, at 2026-06-30−$165.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure(191)Shareholders' equity, Q3 FY2026, at 2026-09-30−$191.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure

Cash flow

Operating cash flow−$25.3m, Q3 FY2026
Capital expenditure$2.7m, Q3 FY2026
PTC Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Operating cash flow$m(100)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$100.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure70.8Operating cash flow, Q1 FY2024, three months to 2024-03-31$70.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure(71.5)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$71.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0001558370-25-010796. Derived: 6-month figure less the 3-month figure.Report this figure(77.0)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$77.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001070081-25-000028. Derived: 9-month figure less the 6-month figure.Report this figure(30.0)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$30.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure870Operating cash flow, Q1 FY2025, three months to 2025-03-31$870.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure(58.3)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$58.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001070081-26-000017. Derived: 6-month figure less the 3-month figure.Report this figure(66.3)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$66.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001104659-26-120223. Derived: 9-month figure less the 6-month figure.Report this figure(34.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$34.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure(59.0)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$59.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure129Operating cash flow, Q2 FY2026, three months to 2026-06-30$129.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0001070081-26-000017. Derived: 6-month figure less the 3-month figure.Report this figure(25.3)Operating cash flow, Q3 FY2026, three months to 2026-09-30−$25.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-10-29, accession 0001104659-26-120223. Derived: 9-month figure less the 6-month figure.Report this figure
Capital expenditure$m5.6Capital expenditure, Q4 FY2023, three months to 2023-12-31$5.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure9.6Capital expenditure, Q1 FY2024, three months to 2024-03-31$9.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure(7.4)Capital expenditure, Q2 FY2024, three months to 2024-06-30−$7.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0001558370-25-010796. Derived: 6-month figure less the 3-month figure.Report this figure0.5Capital expenditure, Q3 FY2024, three months to 2024-09-30$522.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001070081-25-000028. Derived: 9-month figure less the 6-month figure.Report this figure3.8Capital expenditure, Q4 FY2024, three months to 2024-12-31$3.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure1.7Capital expenditure, Q1 FY2025, three months to 2025-03-31$1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure1.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001070081-26-000017. Derived: 6-month figure less the 3-month figure.Report this figure3.5Capital expenditure, Q3 FY2025, three months to 2025-09-30$3.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001104659-26-120223. Derived: 9-month figure less the 6-month figure.Report this figure2.4Capital expenditure, Q4 FY2025, three months to 2025-12-31$2.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-19, accession 0001104659-26-017575. Derived: 12-month figure less the 9-month figure.Report this figure1.2Capital expenditure, Q1 FY2026, three months to 2026-03-31$1.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure2.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$2.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0001070081-26-000017. Derived: 6-month figure less the 3-month figure.Report this figure2.7Capital expenditure, Q3 FY2026, three months to 2026-09-30$2.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-10-29, accession 0001104659-26-120223. Derived: 9-month figure less the 6-month figure.Report this figure

Shares

Diluted shares (weighted)83.48m, Q3 FY2026
PTC Therapeutics, Inc., shares, quarterly
Line itemUnitQ1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30Q3 FY20262026-09-30
Diluted shares (weighted)m shares73.7Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3173,729,284 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-04-25, accession 0001558370-24-005782.Report this figure74.7Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3074,730,433 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0001070081-24-000017.Report this figure75.4Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3075,377,997 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0001070081-24-000023.Report this figure76.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3176,496,127 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-06, accession 0001070081-25-000019.Report this figure76.7Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3076,725,070 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0001558370-25-010796.Report this figure76.9Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3076,925,523 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-04, accession 0001070081-25-000028.Report this figure86.4Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3186,385,922 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure78.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3078,151,240 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure87.1Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3087,115,369 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure82.5Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3182,521,023 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-07, accession 0001070081-26-000012.Report this figure92.0Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3092,020,009 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-07-30, accession 0001070081-26-000017.Report this figure83.5Diluted shares (weighted), Q3 FY2026, three months to 2026-09-3083,476,100 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure

Shares outstanding: 83.54mShares outstanding, period not labelled, at 2026-10-2783,544,284 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-10-29, accession 0001104659-26-120223.Report this figure at Oct 27, 2026, from the cover of the 10-Q filed Oct 29, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 18:45 ET. Listed shows no prices and gives no investment advice.